Abstract
Renal allografting is the only long-term alternative to euthanasia in dogs with end-stage kidney disease. The purpose of this study was to determine the clinical, biochemical, and hematologic effects of rabbit anti-dog thymocyte serum (RADTS) in normal dogs and to develop a safe and practical route of administration before its use in an allograft immunosuppressive protocol. Thirteen mongrel dogs were divided into three groups; each received RADTS subcutaneously, intramuscularly, or intravenously. The inflammation and pain associated with subcutaneous administration was unacceptable. A significant (p < or = .05) leukopenia and lymphopenia developed in all dogs, regardless of the route of administration of RADTS. Thrombocytopenia was a consistent finding after intravenous administration and with high doses given intramuscularly. Both the intravenous and intramuscular routes were well tolerated by all dogs with minimal or no discomfort. Serum creatinine was unchanged, whereas serum alanine aminotransferase activity increased in one dog. There were no histologic changes in any of the kidneys examined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
